Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026

Loading news article.

Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026 | WAPE

Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026

Article summary

Related companies

Comments —